
============================================================
                    AKTIENANALYSE: CRSP                     
============================================================
Firmendaten werden abgerufen...
+-------------+------------------------+------------------------------+
| Kategorie   | Details                | ErlÃ¤uterung                  |
+=============+========================+==============================+
| Unternehmen | CRISPR Therapeutics AG | Name des Unternehmens        |
+-------------+------------------------+------------------------------+
| Sektor      | Healthcare             | Wirtschaftssektor            |
+-------------+------------------------+------------------------------+
| Branche     | Biotechnology          | Industrie oder GeschÃ¤ftsfeld |
+-------------+------------------------+------------------------------+
| Land        | Switzerland            | Herkunftsland                |
+-------------+------------------------+------------------------------+

Kurzbeschreibung: CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISP...

Historische Daten werden abgerufen...
Historische Daten erfolgreich abgerufen.

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
            KURSVERLAUF VISUALISIERUNG            
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
ASCII-ART KURSVERLAUF (Letzte 90 Tage)
Hoch: 53.02 | Tief: 31.27
--------------------------------------------------
     *                                                                                    
    *                                                                                     
   *  *                                                                                   
       **                                                                                 
  *      **** ** *  *                                                                   **
 *           *  * ** ********                                                   ********  
*                            **           ***   ***   *           ***          *          
                               **            ***   *** ***  * ** *   **********           
                                 * *    **                 * *  *                         
                                  * ****                  *                               
--------------------------------------------------
Datenpunkte: Jeder * reprÃ¤sentiert einen Tag

PERFORMANCE VERGLEICH (Letzte 252 Handelstage)
--------------------------------------------------
CRSP                : -26.94%
S&P500              : +8.76%
--------------------------------------------------
CRSP hat den S&P500 underperformt.

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
                TECHNISCHE ANALYSE                
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
+----------------+--------+---------------------------------+
| Kategorie      | Wert   | ErlÃ¤uterung                     |
+================+========+=================================+
| Aktueller Kurs | $44.25 | Letzter Schlusskurs             |
+----------------+--------+---------------------------------+
| TagesÃ¤nderung  | -0.4%  | Prozentuale Ã„nderung zum Vortag |
+----------------+--------+---------------------------------+
| Volumen        | N/A    | Gehandeltes Volumen             |
+----------------+--------+---------------------------------+
| MA(20)         | $39.92 | 20-Tage-Durchschnitt            |
+----------------+--------+---------------------------------+
| MA(50)         | $38.40 | 50-Tage-Durchschnitt            |
+----------------+--------+---------------------------------+
| MA(200)        | $43.09 | 200-Tage-Durchschnitt           |
+----------------+--------+---------------------------------+
| RSI(14)        | 84.2   | Relative Strength Index         |
+----------------+--------+---------------------------------+
| 52W Hoch       | $91.10 | 52-Wochen-HÃ¶chstkurs            |
+----------------+--------+---------------------------------+
| 52W Tief       | $30.04 | 52-Wochen-Tiefstkurs            |
+----------------+--------+---------------------------------+
| VolatilitÃ¤t    | 56.7%  | JÃ¤hrliche VolatilitÃ¤t           |
+----------------+--------+---------------------------------+

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
             FUNDAMENTALE KENNZAHLEN              
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
+----------------------+-------------------+-----------------------------------------+
| Kategorie            | Wert              | ErlÃ¤uterung                             |
+======================+===================+=========================================+
| Marktkapitalisierung | $3,821,593,600.00 | Gesamtwert der Aktien                   |
+----------------------+-------------------+-----------------------------------------+
| KGV (P/E)            | N/A               | Kurs-Gewinn-VerhÃ¤ltnis                  |
+----------------------+-------------------+-----------------------------------------+
| Forward P/E          | -8.78             | Erwartetes KGV                          |
+----------------------+-------------------+-----------------------------------------+
| Dividendenrendite    | N/A               | Dividende im VerhÃ¤ltnis zum Kurs        |
+----------------------+-------------------+-----------------------------------------+
| Verschuldungsgrad    | 11.99             | VerhÃ¤ltnis von Schulden zu Eigenkapital |
+----------------------+-------------------+-----------------------------------------+

Bewertung der fundamentalen Kennzahlen:
- debt_to_equity: Schlecht (hohe Verschuldung)

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
               ANALYSTENSCHÃ„TZUNGEN               
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
+--------------------+--------+------------------------------+
| Kategorie          | Wert   | ErlÃ¤uterung                  |
+====================+========+==============================+
| Analysten-Kursziel | $81.67 | Durchschnittliches Kursziel  |
+--------------------+--------+------------------------------+
| Upside-Potenzial   | 84.6%  | Potenzial fÃ¼r Kurssteigerung |
+--------------------+--------+------------------------------+

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
            DCF SCHÃ„TZUNG & SZENARIEN             
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
DCF SchÃ¤tzung nicht mÃ¶glich (unzureichende Daten oder FCF ist 0).

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
               SENSITIVITÃ„TSANALYSE               
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
+-----------------+----------------------+------------+
| Wachstumsrate   | Diskontierungsrate   | DCF Wert   |
+=================+======================+============+
| Wachstum 0.0%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.0%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.0%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.1%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.1%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.1%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.1%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.1%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+
| Wachstum 0.1%   | Diskontierung 0.1%   | N/A        |
+-----------------+----------------------+------------+

==============================
Gesamtbewertung abgeschlossen 
==============================

+-------------+------------------------+------------------------------+
| Kategorie   | Details                | ErlÃ¤uterung                  |
+=============+========================+==============================+
| Unternehmen | CRISPR Therapeutics AG | Name des Unternehmens        |
+-------------+------------------------+------------------------------+
| Sektor      | Healthcare             | Wirtschaftssektor            |
+-------------+------------------------+------------------------------+
| Branche     | Biotechnology          | Industrie oder GeschÃ¤ftsfeld |
+-------------+------------------------+------------------------------+
| Land        | Switzerland            | Herkunftsland                |
+-------------+------------------------+------------------------------+
+----------------+--------+---------------------------------+
| Kategorie      | Wert   | ErlÃ¤uterung                     |
+================+========+=================================+
| Aktueller Kurs | $44.25 | Letzter Schlusskurs             |
+----------------+--------+---------------------------------+
| TagesÃ¤nderung  | -0.4%  | Prozentuale Ã„nderung zum Vortag |
+----------------+--------+---------------------------------+
| Volumen        | N/A    | Gehandeltes Volumen             |
+----------------+--------+---------------------------------+
| MA(20)         | $39.92 | 20-Tage-Durchschnitt            |
+----------------+--------+---------------------------------+
| MA(50)         | $38.40 | 50-Tage-Durchschnitt            |
+----------------+--------+---------------------------------+
| MA(200)        | $43.09 | 200-Tage-Durchschnitt           |
+----------------+--------+---------------------------------+
| RSI(14)        | 84.2   | Relative Strength Index         |
+----------------+--------+---------------------------------+
| 52W Hoch       | $91.10 | 52-Wochen-HÃ¶chstkurs            |
+----------------+--------+---------------------------------+
| 52W Tief       | $30.04 | 52-Wochen-Tiefstkurs            |
+----------------+--------+---------------------------------+
| VolatilitÃ¤t    | 56.7%  | JÃ¤hrliche VolatilitÃ¤t           |
+----------------+--------+---------------------------------+
+----------------------+-------------------+-----------------------------------------+
| Kategorie            | Wert              | ErlÃ¤uterung                             |
+======================+===================+=========================================+
| Marktkapitalisierung | $3,821,593,600.00 | Gesamtwert der Aktien                   |
+----------------------+-------------------+-----------------------------------------+
| KGV (P/E)            | N/A               | Kurs-Gewinn-VerhÃ¤ltnis                  |
+----------------------+-------------------+-----------------------------------------+
| Forward P/E          | -8.78             | Erwartetes KGV                          |
+----------------------+-------------------+-----------------------------------------+
| Dividendenrendite    | N/A               | Dividende im VerhÃ¤ltnis zum Kurs        |
+----------------------+-------------------+-----------------------------------------+
| Verschuldungsgrad    | 11.99             | VerhÃ¤ltnis von Schulden zu Eigenkapital |
+----------------------+-------------------+-----------------------------------------+
+--------------------+--------+------------------------------+
| Kategorie          | Wert   | ErlÃ¤uterung                  |
+====================+========+==============================+
| Analysten-Kursziel | $81.67 | Durchschnittliches Kursziel  |
+--------------------+--------+------------------------------+
| Upside-Potenzial   | 84.6%  | Potenzial fÃ¼r Kurssteigerung |
+--------------------+--------+------------------------------+

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
           AKTIENSTRATEGIE & EMPFEHLUNG           
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
+-------------------+----------------------------------------------------+--------------------------------------------+
| Kategorie         | Wert                                               | ErlÃ¤uterung                                |
+===================+====================================================+============================================+
| Kategorie         | Wert                                               | ErlÃ¤uterung                                |
+-------------------+----------------------------------------------------+--------------------------------------------+
| Gesamtempfehlung  | ðŸŸ¡ Halten                                           | Zusammenfassende Bewertung der Aktie.      |
+-------------------+----------------------------------------------------+--------------------------------------------+
| StÃ¤rken           | Keine besonderen StÃ¤rken                           | Positive Aspekte der Analyse.              |
+-------------------+----------------------------------------------------+--------------------------------------------+
| SchwÃ¤chen/Risiken | Hoher Verschuldungsgrad,                           | Negative Aspekte oder potenzielle Risiken. |
|                   | Ãœberkauft (RSI)                                    |                                            |
+-------------------+----------------------------------------------------+--------------------------------------------+
| BegrÃ¼ndung        | Forward P/E: -8.78, Dividende: N/A, DCF: N/A (EUR) | GrÃ¼nde fÃ¼r die Bewertung.                  |
+-------------------+----------------------------------------------------+--------------------------------------------+
| Kaufzone          | N/A (EUR)                                          | Preisbereich fÃ¼r den Einstieg.             |
+-------------------+----------------------------------------------------+--------------------------------------------+

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
                DIVIDENDENWACHSTUM                
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Keine ausreichenden Daten fÃ¼r Dividendenwachstum verfÃ¼gbar.
